Cancer Progression
Cancer Progression - Related Videos
09:25
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
0 Views •
Cited by 34 •
2013
Improved understanding of pancreatic cancer biology is critically needed to enable the development of better therapeutic options to treat pancreatic cancer. To address this need, we demonstrate an orthotopic model of pancreatic cancer that permits non-invasive monitoring of cancer progression using in vivo bioluminescence imaging.
03:03
mTOR Signaling and Cancer Progression
0 Views •
2023
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
03:03
mTOR Signaling and Cancer Progression
0 Views •
2021
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
03:19
Generating PDOX Mouse Model of Colorectal Cancer: Studying Progression of Colorectal Cancer in a Murine Model
0 Views •
2023
This video describes the protocol for generating a patient-derived orthotopic xenograft colorectal cancer mouse model to study the progression of colorectal cancer cells in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. This murine model helps in understanding primary tumor growth and metastases pattern.
28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
0 Views •
Cited by 22 •
2010
Reduced/absent expression of Pms2 and/or ERCC1 in entire crypts is a frequent event within 10 cm on each side of colonic adenocarcinomas, likely the basis of a field defect with high mutability and progression to cancer. Deficiency in Ku86 or CcOI is much less frequent in these field defects.
FAQs
Genetic and epigenetic alterations can disrupt controls over cell division, survival, and genome stability. These changes give abnormal cells opportunities to persist and expand when normal regulatory restraints no longer function properly. In biological research, examining these alterations helps connect molecular changes with the progressive acquisition of tumor-related traits and supports the search for biomarkers associated with disease development.
Natural selection favors tumor cell clones whose altered traits improve growth, survival, or expansion within their environment. As these clones become more prevalent, the tumor can acquire increasingly aggressive properties rather than remaining biologically uniform. This evolutionary perspective helps researchers interpret Cancer Progression as a changing population of cells and explains why later tumor behavior may differ from earlier stages.
Angiogenesis, the stimulation of new blood-vessel growth, can support an expanding tumor by helping it obtain resources. At the same time, evading immune responses allows abnormal cells to persist instead of being eliminated. Together, these properties contribute to tumor advancement and give researchers biologically distinct features to investigate when studying how Cancer Progression affects growth and survival.
Metastatic spread requires cells to breach surrounding tissue, enter blood or lymphatic systems, and later establish secondary tumors in distant organs. These steps represent a progression from localized growth toward systemic disease. Tracking them helps distinguish local invasion from dissemination and provides a biological framework for studying why some tumors develop distant sites while others remain more contained.
Researchers examine the biological changes associated with tumor growth, invasion, immune evasion, and metastatic spread to support disease classification. These features can help identify biomarkers, measurable indicators linked to particular biological states, and distinguish stages of cancer. The resulting information connects cellular behavior with clinical research needs, including characterization of disease severity and comparison of tumor progression patterns.
Cancer Progression research links specific biological changes with the traits that make tumors grow, invade tissue, evade immune responses, or spread. That connection helps investigators identify vulnerabilities associated with particular tumor behaviors and evaluate targets for treatment development. In biology and clinical research, this approach supports the design of targeted treatments informed by the mechanisms driving an individual tumor’s advancement.